Opinions
The growing need to monitor the liver function after SARS-CoV-2 infection in the Mexican population with obesity
Juan José Rivera-Valdesa, Erika Martínez-Lopeza,
Corresponding author
erikamtz27@yahoo.com.mx
Corresponding author at: Instituto de Nutrigenética y Nutrigenómica Traslacional, Departamento de Biologia Molecular y Genómica, Guadalajara, Jalisco, 44340, Mexico.
Corresponding author at: Instituto de Nutrigenética y Nutrigenómica Traslacional, Departamento de Biologia Molecular y Genómica, Guadalajara, Jalisco, 44340, Mexico.
a Instituto de Nutrigenética y Nutrigenómica Traslacional, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México, Sierra Mojada 950, Guadalajara, Jalisco, Mexico.
Read
1046
Timeswas read the article
258
Total PDF
788
Total HTML
Share statistics
array:24 [ "pii" => "S1665268122000400" "issn" => "16652681" "doi" => "10.1016/j.aohep.2022.100698" "estado" => "S300" "fechaPublicacion" => "2022-05-01" "aid" => "100698" "copyright" => "Fundación Clínica Médica Sur, A.C." "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "dis" "cita" => "Ann Hepatol. 2022;27:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:19 [ "pii" => "S1665268122000230" "issn" => "16652681" "doi" => "10.1016/j.aohep.2022.100681" "estado" => "S300" "fechaPublicacion" => "2022-05-01" "aid" => "100681" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2022;27:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Identification of key genes associated with the progression of liver fibrosis to hepatocellular carcinoma based on iTRAQ proteomics and GEO database" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1100 "Ancho" => 2167 "Tamanyo" => 193513 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "alt0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spara005" class="elsevierStyleSimplePara elsevierViewall">Wayne diagram of DEPs in rat liver tissues after CCl<span class="elsevierStyleInf">4</span> stimulation. (A) Upregulated proteins. (B) Downregulated proteins.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jiongyi Yan, Xuewan Fang, Yinyi Feng, Xiaojuan Cui, Fang Li, Weisheng Luo, Xiaocong Ma, Jianqin Liang, Jianfang Feng" "autores" => array:9 [ 0 => array:2 [ "nombre" => "Jiongyi" "apellidos" => "Yan" ] 1 => array:2 [ "nombre" => "Xuewan" "apellidos" => "Fang" ] 2 => array:2 [ "nombre" => "Yinyi" "apellidos" => "Feng" ] 3 => array:2 [ "nombre" => "Xiaojuan" "apellidos" => "Cui" ] 4 => array:2 [ "nombre" => "Fang" "apellidos" => "Li" ] 5 => array:2 [ "nombre" => "Weisheng" "apellidos" => "Luo" ] 6 => array:2 [ "nombre" => "Xiaocong" "apellidos" => "Ma" ] 7 => array:2 [ "nombre" => "Jianqin" "apellidos" => "Liang" ] 8 => array:2 [ "nombre" => "Jianfang" "apellidos" => "Feng" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268122000230?idApp=UINPBA00004N" "url" => "/16652681/0000002700000003/v2_202205130853/S1665268122000230/v2_202205130853/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S166526812200045X" "issn" => "16652681" "doi" => "10.1016/j.aohep.2022.100703" "estado" => "S300" "fechaPublicacion" => "2022-05-01" "aid" => "100703" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "edi" "cita" => "Ann Hepatol. 2022;27:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:8 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorials</span>" "titulo" => "Is diabetes a risk factor for malignancy post-transplant in liver transplant recipients?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Stephen E. Congly" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Stephen E." "apellidos" => "Congly" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S166526812200045X?idApp=UINPBA00004N" "url" => "/16652681/0000002700000003/v2_202205130853/S166526812200045X/v2_202205130853/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Opinions</span>" "titulo" => "The growing need to monitor the liver function after SARS-CoV-2 infection in the Mexican population with obesity" "tieneTextoCompleto" => true "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Juan José Rivera-Valdes, Erika Martínez-Lopez" "autores" => array:2 [ 0 => array:3 [ "nombre" => "Juan José" "apellidos" => "Rivera-Valdes" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] ] ] 1 => array:4 [ "nombre" => "Erika" "apellidos" => "Martínez-Lopez" "email" => array:1 [ 0 => "erikamtz27@yahoo.com.mx" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0001" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0001" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Instituto de Nutrigenética y Nutrigenómica Traslacional, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México, Sierra Mojada 950, Guadalajara, Jalisco, Mexico." "etiqueta" => "a" "identificador" => "aff0001" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0001" "etiqueta" => "⁎" "correspondencia" => "Corresponding author at: Instituto de Nutrigenética y Nutrigenómica Traslacional, Departamento de Biologia Molecular y Genómica, Guadalajara, Jalisco, 44340, Mexico." ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="para0001" class="elsevierStylePara elsevierViewall">The current Coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a major public health problem over the last two years. It has reached 418,650,474 confirmed cases of COVID-19, including 5.856.224 deaths, until February 2022, according to the World Health Organization <a class="elsevierStyleCrossRef" href="#bib0001">[1]</a>. Unfortunately, Mexico was already dealing with obesity, another public health problem. In Mexico, the reported 2018 prevalence of obesity in adults was 36.1% <a class="elsevierStyleCrossRef" href="#bib0002">[2]</a>. Obesity, along with its underlying comorbidities, such as hypertension, diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease are major factors predicting poor COVID-19 outcomes. In this sense, the pre-pandemic prevalence of obesity and chronic and metabolic diseases in Mexico may be related to the high COVID-19 associated lethality rate in the region <a class="elsevierStyleCrossRef" href="#bib0003">[3]</a>.</p><p id="para0002" class="elsevierStylePara elsevierViewall">Much has been speculated about the possible consequences and long-term effects for those who have been infected by SARS-CoV-2. While the most recognized sequelae are cardiac, sensitive, and respiratory conditions; an organ that also has cells with entry pathway receptors for SARS‐CoV-2 has been left out. Angiotensin-converting enzyme 2 receptors are the main viral entry point for SARS-CoV-2 <a class="elsevierStyleCrossRef" href="#bib0004">[4]</a>, and they are highly expressed in the lung and kidney, but are also expressed in gastrointestinal tract, vascular endothelium and cholangiocytes of the liver [<a class="elsevierStyleCrossRef" href="#bib0005">5</a>, <a class="elsevierStyleCrossRef" href="#bib0006">6</a>], which is relevant because it positions the liver as a potential target for SARS-CoV-2.</p><p id="para0003" class="elsevierStylePara elsevierViewall">In this sense, the term “COVID-19 associated liver injury” has emerged to define any liver damage that occurs during illness and treatment of patients with COVID-19, with or without pre-existing liver disease <a class="elsevierStyleCrossRef" href="#bib0007">[7]</a>. COVID-19 affects multiple organs, including anomalies in liver function <a class="elsevierStyleCrossRef" href="#bib0008">[8]</a>. Even though studies that determine liver function biomarkers in Mexican patients with COVID-19 are scarce, they coincide in the detection of abnormal values ​​of hepatic transaminases, whose elevated levels reflect liver damage are common in patients with COVID-19, both for those with and without chronic liver disease (CLD). A recent study in which the majority of its population had overweight and obesity investigated the effects of the SARS-CoV-2 virus on liver function and its association with the severity of acute respiratory distress syndrome in Mexican population found a high frequency of patients who have alterations in liver function tests (LFTs), especially aspartate aminotransferase (AST) and gamma glutamyl Transferase (GGT) <a class="elsevierStyleCrossRef" href="#bib0009">[9]</a>. Another study reported that higher levels of alanine aminotransferase (ALT) are associated with higher in-hospital mortality risk in Mexican patients admitted with COVID-19 <a class="elsevierStyleCrossRef" href="#bib0002">[2]</a>. Abnormal LFTs on admission have been given the role of diagnostic biomarkers, for manifesting within the first 7 days of infection, and for their prognostic value during the disease <a class="elsevierStyleCrossRef" href="#bib0010">[10]</a>; even they have been associated, both independently and together with obesity, with mortality and severe COVID-19 in hospitalized patients with SARS-CoV-2 infection and its use as a surrogate marker of inflammation has been suggested <a class="elsevierStyleCrossRef" href="#bib0011">[11]</a>.</p><p id="para0004" class="elsevierStylePara elsevierViewall">On the one hand, the diagnostic and predictive value of liver markers during COVID-19 is undeniable; on the other hand, it is still unknown the long-term effects of the COVID-19 associated liver injury, for both obese and non-obese patients. However, a possible bridge between obesity, COVID-19 and LFTs alterations could be NAFLD, since NAFLD is the most frequently liver disease associated with obesity, and recently is predicted to be present in the majority of COVID-19 patients with pre-existing CLD worldwide <a class="elsevierStyleCrossRef" href="#bib0012">[12]</a>. Evidence indicates that SARS-CoV-2 can infect the liver and cause conspicuous hepatic cytopathic injury. Microvesicular and macrovesicular steatosis have been observed in liver autopsies of COVID-19 patients who presented SARS-CoV-2 infection as the only risk factor for liver injury. A recent prospective cohort evaluated the histopathological evolution during COVID-19, and observed prominent dilation of the sinusoids in all liver biopsies, regardless of the stage of the disease, while the presence of lobular inflammation was limited to patients with mild or moderate COVID-19 <a class="elsevierStyleCrossRef" href="#bib0013">[13]</a>. Other histopathological findings in SARS-CoV-2-infected livers include mild lobular and portal activity, massive apoptosis, and binuclear hepatocytes with notable mitochondrial inflammation, endoplasmic reticulum dilation <a class="elsevierStyleCrossRef" href="#bib0014">[14]</a>. In this sense, it has been suggested that one of the cytopathic effects of SARS-CoV-2 is through the deregulation of the host lipid metabolism and mitochondrial activity. Other possible pathological mechanism involve the viral S protein, which could be capable of inducing stress in endoplasmic reticulum, and this in turn induce <span class="elsevierStyleItalic">de novo</span> lipogenesis, which could contribute to the development of steatosis in patients with COVID-19 <a class="elsevierStyleCrossRef" href="#bib0007">[7]</a>. This is relevant because NAFLD is an important cause of more severe pathologies such as liver cirrhosis and hepatocellular carcinoma. However, there is a great need for studies that confirm these hypotheses; as long-term follow-up studies are also required to explore potential sequelae of SARS-CoV-2 infection.</p><p id="para0005" class="elsevierStylePara elsevierViewall">Even though the mechanism by which COVID-19 causes liver injury and disfunction has not yet been clarified, the most prominent explanations are (a) immune-mediated damage due to the severe inflammatory response following infection, (b) direct cytopathic effect of SARS‐CoV‐2 in hepatic tissue, and (c) drug-induced liver injury <a class="elsevierStyleCrossRef" href="#bib0012">[12]</a>. At this point, it is important to note that certain medications commonly used during hospitalization, including corticoids, antiretroviral agents, and methotrexate, contribute to abnormal liver function test results of COVID-19 patients <a class="elsevierStyleCrossRef" href="#bib0015">[15]</a> and might trigger the transition of simple fatty liver to non-alcoholic steatohepatitis or worsen pre-existing steatosis, necroinflammation, and fibrosis <a class="elsevierStyleCrossRef" href="#bib0012">[12]</a>. Although it is not yet clear whether SARS‐CoV‐2 directly or the medication used for its treatment is the main cause of liver damage during and after COVID-19; it should be taken into account when providing treatment for these patients, prioritizing the use of drugs that are capable of inhibiting the inflammatory response while protecting liver function <a class="elsevierStyleCrossRef" href="#bib0008">[8]</a>.</p><p id="para0006" class="elsevierStylePara elsevierViewall">Finally, LFTs should be routinely ordered to assess relative liver injury in patients diagnosed with COVID-19. The general recommendation for all patients in the mild category with associated comorbidity or patients in moderate category at hospital admission includes LFTs along with a complete blood count, C-reactive protein, and serum creatinine. If any of these markers are abnormal, further investigations for patients in severe category may be considered <a class="elsevierStyleCrossRef" href="#bib0010">[10]</a>. In Mexico, the need to monitor liver function should be added to the recommendation for those who have survived the mild and severe COVID-19 disease, especially those with metabolic disorders, also for cases of people who have been reinfected by the virus, due to the possibility of presenting liver disorders after infection; as well as for those people who have pre-existing CLD during COVID-19, to determine the aggravation by SARS‐CoV‐2. The effects of COVID-19 on underlying CLD require detailed evaluation and further research is warranted in this area.</p><span id="sec0001" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0003">Abbreviations</span><p id="para0007" class="elsevierStylePara elsevierViewall">ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLD, chronic liver disease; COVID-19, coronavirus disease 2019; LFTs, liver function tests; NAFLD, Nonalcoholic fatty liver disease; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus‐2; WHO, World Health Organization.</p></span><span id="sec0002" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0004">Declaration of Competing Interest</span><p id="para0008" class="elsevierStylePara elsevierViewall">The authors have not conflicts of interest</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:4 [ 0 => array:2 [ "identificador" => "xpalclavsec1511776" "titulo" => "Keywords" ] 1 => array:2 [ "identificador" => "sec0001" "titulo" => "Abbreviations" ] 2 => array:2 [ "identificador" => "sec0002" "titulo" => "Declaration of Competing Interest" ] 3 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2022-02-23" "fechaAceptado" => "2022-02-28" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1511776" "palabras" => array:5 [ 0 => "SARS-Cov-2" 1 => "COVID-19" 2 => "Liver function" 3 => "AST" 4 => "Steatosis" ] ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "cebibsec1" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib0001" "etiqueta" => "[1]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "World Health Organization" "etal" => false ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "WHO" "fecha" => "2021" "paginaInicial" => "1" "paginaFinal" => "5" ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "https://covid19.who.int/" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0002" "etiqueta" => "[2]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico: a multi-centre retrospective cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Vidal-Cevallos" 1 => "F. Higuera-De-La-Tijera" 2 => "N.C. Chávez-Tapia" 3 => "F. Sanchez-Giron" 4 => "E. Cerda-Reyes" 5 => "V.H. Rosales-Salyano" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/J.AOHEP.2021.100338" "Revista" => array:3 [ "tituloSerie" => "Ann Hepatol" "fecha" => "2021" "volumen" => "24" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0003" "etiqueta" => "[3]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Latin America and chronic diseases: A perfect storm during the COVID-19 pandemic" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A. Pizuorno" 1 => "NA. Fierro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/J.AOHEP.2021.100332" "Revista" => array:3 [ "tituloSerie" => "Ann Hepatol" "fecha" => "2021" "volumen" => "22" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0004" "etiqueta" => "[4]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W. Li" 1 => "M.J. Moore" 2 => "N. Vasllieva" 3 => "J. Sui" 4 => "S.K. Wong" 5 => "M.A. Berne" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/NATURE02145" "Revista" => array:5 [ "tituloSerie" => "Nature" "fecha" => "2003" "volumen" => "426" "paginaInicial" => "450" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14647384" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0005" "etiqueta" => "[5]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A novel ACE2 isoform is expressed in human respiratory epithelia and is upregulated in response to interferons and RNA respiratory virus infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Blume" 1 => "C.L. Jackson" 2 => "C.M. Spalluto" 3 => "J. Legebeke" 4 => "L. Nazlamova" 5 => "F. Conforti" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41588-020-00759-x" "Revista" => array:6 [ "tituloSerie" => "Nat Genet" "fecha" => "2021" "volumen" => "53" "paginaInicial" => "205" "paginaFinal" => "214" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33432184" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0006" "etiqueta" => "[6]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 and the liver" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "D. Jothimani" 1 => "R. Venugopal" 2 => "M.F. Abedin" 3 => "I. Kaliamoorthy" 4 => "M. Rela" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/J.JHEP.2020.06.006" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2020" "volumen" => "73" "paginaInicial" => "1231" "paginaFinal" => "1240" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32553666" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0007" "etiqueta" => "[7]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathophysiological mechanisms of liver injury in COVID-19" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A.D. Nardo" 1 => "M. Schneeweiss-Gleixner" 2 => "M. Bakail" 3 => "E.D. Dixon" 4 => "S.F. Lax" 5 => "M. Trauner" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/liv.14730" "Revista" => array:6 [ "tituloSerie" => "Liver Int" "fecha" => "2021" "volumen" => "41" "paginaInicial" => "20" "paginaFinal" => "32" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33190346" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0008" "etiqueta" => "[8]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Liver function in COVID-19 infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D. Przekop" 1 => "E. Gruszewska" 2 => "L. Chrostek" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4254/WJH.V13.I12.1909" "Revista" => array:6 [ "tituloSerie" => "World J Hepatol" "fecha" => "2021" "volumen" => "13" "paginaInicial" => "1909" "paginaFinal" => "1918" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35069997" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0009" "etiqueta" => "[9]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Frequency of hepatic function alteration in mexican patients with COVID-19 and its association with the severity of acute respiratory distress syndrome: preliminary results" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.B. Vera-Heredia" 1 => "M.I. Mejía-Loza" 2 => "EC. Macías-Cortés" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/J.AOHEP.2021.100618" "Revista" => array:3 [ "tituloSerie" => "Ann Hepatol" "fecha" => "2022" "volumen" => "27" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0010" "etiqueta" => "[10]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biomarkers in COVID-19: An Up-To-Date" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Samprathi" 1 => "M. Jayashree" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3389/fped.2017.00001" "Revista" => array:5 [ "tituloSerie" => "Review. Front Pediatr." "fecha" => "2021" "paginaInicial" => "1" "paginaFinal" => "12" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28180126" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0011" "etiqueta" => "[11]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Mendizabal" 1 => "F. Piñero" 2 => "E. Ridruejo" 3 => "M. Anders" 4 => "M.D. Silveyra" 5 => "A. Torre" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/J.AOHEP.2020.100298" "Revista" => array:3 [ "tituloSerie" => "Ann Hepatol" "fecha" => "2021" "volumen" => "21" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0012" "etiqueta" => "[12]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of COVID-19 patients with chronic liver diseases and liver transplants" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "X. Hu" 1 => "L. Sun" 2 => "Z. Guo" 3 => "C. Wu" 4 => "X. Yu" 5 => "J. Li" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Ann Hepatol" "fecha" => "2022" "volumen" => "27" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0013" "etiqueta" => "[13]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Studying the clinical, radiological, histological, microbiological, and immunological evolution during the different COVID-19 disease stages using minimal invasive autopsy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. D'Onofrio" 1 => "L. Keulen" 2 => "A. Vandendriessche" 3 => "J. Dubois" 4 => "R. Cartuyvels" 5 => "M.-.E. Vanden Abeele" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41598-022-05186-y" "Revista" => array:5 [ "tituloSerie" => "Sci Reports 2022 121" "fecha" => "2022" "volumen" => "12" "paginaInicial" => "1" "paginaFinal" => "12" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0014" "etiqueta" => "[14]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pathological findings of COVID-19 associated with acute respiratory distress syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Z. Xu" 1 => "L. Shi" 2 => "Y. Wang" 3 => "J. Zhang" 4 => "L. Huang" 5 => "C. Zhang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2213-2600(20)30076-X" "Revista" => array:6 [ "tituloSerie" => "Lancet Respir Med" "fecha" => "2020" "volumen" => "8" "paginaInicial" => "420" "paginaFinal" => "422" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32085846" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0015" "etiqueta" => "[15]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19: Abnormal liver function tests" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Q. Cai" 1 => "D. Huang" 2 => "H. Yu" 3 => "Z. Zhu" 4 => "Z. Xia" 5 => "Y. Su" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/J.JHEP.2020.04.006/ATTACHMENT/68A90A8B-8E56-44E5-896C-82FF7FCC23A2/MMC3.PDF" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2020" "volumen" => "73" "paginaInicial" => "566" "paginaFinal" => "574" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32298767" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/16652681/0000002700000003/v2_202205130853/S1665268122000400/v2_202205130853/en/main.assets" "Apartado" => array:4 [ "identificador" => "77921" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Opinions" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/16652681/0000002700000003/v2_202205130853/S1665268122000400/v2_202205130853/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268122000400?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 3 | 0 | 3 |
| 2024 October | 15 | 6 | 21 |
| 2024 September | 31 | 5 | 36 |
| 2024 August | 21 | 7 | 28 |
| 2024 July | 25 | 6 | 31 |
| 2024 June | 20 | 7 | 27 |
| 2024 May | 20 | 1 | 21 |
| 2024 April | 21 | 9 | 30 |
| 2024 March | 36 | 5 | 41 |
| 2024 February | 46 | 5 | 51 |
| 2024 January | 28 | 9 | 37 |
| 2023 December | 33 | 7 | 40 |
| 2023 November | 38 | 9 | 47 |
| 2023 October | 40 | 14 | 54 |
| 2023 September | 28 | 5 | 33 |
| 2023 August | 40 | 5 | 45 |
| 2023 July | 15 | 3 | 18 |
| 2023 June | 26 | 5 | 31 |
| 2023 May | 22 | 7 | 29 |
| 2023 April | 16 | 3 | 19 |
| 2023 March | 11 | 4 | 15 |
| 2023 February | 22 | 4 | 26 |
| 2023 January | 21 | 9 | 30 |
| 2022 December | 19 | 9 | 28 |
| 2022 November | 19 | 4 | 23 |
| 2022 October | 20 | 8 | 28 |
| 2022 September | 15 | 8 | 23 |
| 2022 August | 13 | 13 | 26 |
| 2022 July | 15 | 8 | 23 |
| 2022 June | 47 | 14 | 61 |
| 2022 May | 51 | 15 | 66 |
| 2022 April | 7 | 21 | 28 |
| 2022 March | 4 | 23 | 27 |
Show all
